ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: TH-PO577

Urine Biomarkers of Systemic Lupus Erythematosus Identified Using Liquid and Gas Chromatography/Mass Spectrometry (LC-QTOF-MS and GC-QTOF-MS)

Session Information

  • Pathology and Lab Medicine
    November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: Pathology and Lab Medicine

  • 1700 Pathology and Lab Medicine


  • Aroca Martinez, Gustavo, Universidad Simon Bolivar, Barranquilla, Atlántico, Colombia
  • Pacheco, Lisandro, Universidad Simon Bolivar, Barranquilla, Atlántico, Colombia
  • Sánchez, Alejandra Rojo, Universidad Simon Bolivar, Barranquilla, Atlántico, Colombia
  • Carmona Martes, Ada Luz, Universidad del Atlantico, Barranquilla, Átlántico, Colombia
  • Navarro, Elkin, Universidad Simon Bolivar, Barranquilla, Atlántico, Colombia

Systemic lupus erythematosus (SLE or lupus) is a chronic autoimmune disease, and kidney involvement with SLE, lupus nephritis (LN), is a frequent and severe complication of SLE that increases patient morbidity and mortalityis. The current gold standard for classifying LN progression is a renal biopsy, an invasive procedure with potential risks. Undergoing a series of biopsies for monitoring disease progression and treatments is unlikely suitable for patients with LN. Thus, there is an urgent need for non-invasive alternative biomarkers that can facilitate LN class diagnosis. Such biomarkers will be very useful in guiding intervention strategies to mitigate or treat patients with LN. The current study aims to explore new biomarker candidates for non-invasive diagnosis of LN and explore the pathogenic mechanisms that contribute to renal injury.


A metabolomics approach using LC-QTOF-MS in both positive and negative electrospray ionization (ESI) modes and GC-QTOF-MS was developed for comparison of urine metabolic profile of 23 LN patients, 16 SLE patients, and 10 healthy controls (HCs). Differential metabolites were evaluated with univariate (UVA) and multivariate (MVA) analysis using a nonparametric t test, principal component analysis (PCA) and orthogonal partial least squares regression (OPLS-DA).


Both UVA and MVA showed a clear discrimination in the urinary metabolome between LN, SLE and HCs. The significant altered metabolites between LN and SLE correspond mainly to fatty acyls, amino acids, bile acids in particular methylglutamic acid, monopalmitin methyl-L-proline, 3-oxo-4-pentenoic acid, glutaric acid, 3-hydroxyglutaric acid, citraconic acid, glutamine, glycocholic acid and ureidoisobutyric acid. Analysis of metabolic pathways shows disturbances in biosynthesis of alanine, aspartate and glutamate metabolism, citrate cycle (TCA cycle) and glutamine and glutamate metabolism.


The urinary metabolome of SLE and LN patients made it possible to determine metabolic alterations and discriminate LN patients from SLE patients. If confirmed in larger studies, these urine metabolites may serve as biomarkers to help discriminate between SLE with and without renal involvement.